Cargando…

Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas

Rhabdoid meningiomas (RM) shows heterogeneous histological findings, and a wide variety of chromosomal copy number alterations (CNA) are associated with an unpredictable course of the disease. In this study, we analyzed a series of 305 RM samples from patients previously reported in the literature a...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido Ruiz, Patricia Alejandra, González-Tablas, María, Pasco Peña, Alejandro, Zelaya Huerta, María Victoria, Ortiz, Javier, Otero, Álvaro, Corchete, Luis Antonio, Ludeña, María Dolores, Caballero Martínez, María Cristina, Córdoba Iturriagagoitia, Alicia, Fernández, Inmaculada Catalina, González-Carreró Fojón, Joaquín, Hernández Laín, Aurelio, Orfao, Alberto, Tabernero, María Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865044/
https://www.ncbi.nlm.nih.gov/pubmed/36674634
http://dx.doi.org/10.3390/ijms24021116
Descripción
Sumario:Rhabdoid meningiomas (RM) shows heterogeneous histological findings, and a wide variety of chromosomal copy number alterations (CNA) are associated with an unpredictable course of the disease. In this study, we analyzed a series of 305 RM samples from patients previously reported in the literature and 33 samples from 23 patients studied in our laboratory. Monosomy 22-involving the minimal but most common recurrent region loss of the 22q11.23 chromosomal region was the most observed chromosomal alteration, followed by losses of chromosomes 14, 1, 6, and 19, polysomies of chromosomes 17, 1q, and 20, and gains of 13q14.2, 10p13, and 21q21.2 chromosomal regions. Based on their CNA profile, RM could be classified into two genetic subgroups with distinct clinicopathologic features characterized by the presence of (1) chromosomal losses only and (2) combined losses and gains of several chromosomes. The latter displays a higher frequency of WHO grade 3 tumors and poorer clinical outcomes.